Navitas Semiconductor (NVTS) Is Down 7.4% After Weak Q2 Results and Cautious Q3 Outlook – What's Changed

In the past week, Navitas Semiconductor reported second quarter results showing sales of US$14.49 million and a net loss of US$49.08 million, alongside forward guidance forecasting third-quarter revenues of US$10.0 million, plus or minus US$0.5 million, due to China tariff risks and a more selective mobile strategy. Xiaomi announced that its next-generation 90W GaN charger will use Navitas' GaNSense Control ICs, highlighting industry adoption of Navitas’ advanced power semiconductor technology despite current financial headwinds. We'll examine how the sharp year-over-year decline in revenue and wider losses impact Navitas Semiconductor’s investment narrative and strategic outlook. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.Navitas Semiconductor Investment Narrative Recap To be a shareholder in Navitas Semiconductor requires confidence in the company's long-term ability to translate advanced GaN and SiC power technology into sustained revenue growth, especially within high-value sectors like AI data centers and industrial infrastructure. This quarter's steep revenue drop and expanded net losses sharpen concerns about near-term cash burn, but do not materially shift the biggest short-term catalyst, accelerating design wins in premium markets, or the key risk of prolonged revenue weakness during the strategic transition. Of the recent updates, Xiaomi's choice to feature Navitas' GaNSense Control ICs in its new 90W GaN charger stands out. This customer win supports the underlying investment narrative of strong technology adoption and validates Navitas' premium product positioning, even as the company contends with China-related tariff risks and a narrower mobile focus in the near term. However, against this backdrop, investors should be aware that a prolonged decline in Chinese demand could... Read the full narrative on Navitas Semiconductor (it's free!)Navitas Semiconductor's outlook anticipates $153.5 million in revenue and $22.1 million in earnings by 2028. This implies a 31.1% annual revenue growth rate and a $146.6 million increase in earnings from -$124.5 million today.Uncover how Navitas Semiconductor's forecasts yield a $6.74 fair value, in line with its current price.Exploring Other PerspectivesNVTS Community Fair Values as at Aug 2025 Ten fair value estimates from the Simply Wall St Community range from US$2.10 to US$26.76 per share. While some see significant upside, market consensus continues to highlight the major risk of persistent revenue declines and ongoing cash burn during the portfolio shift, reminding you to consider these opposing views. Explore 10 other fair value estimates on Navitas Semiconductor - why the stock might be worth over 3x more than the current price!Build Your Own Navitas Semiconductor NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Navitas Semiconductor research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.Our free Navitas Semiconductor research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Navitas Semiconductor's overall financial health at a glance.Contemplating Other Strategies?Opportunities like this don't last. These are today's most promising picks. Check them out now:Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.